Acadia Healthcare stock saw its IBD SmartSelect Composite Rating rise to 96 Friday, up from 94 the day before.
The upgrade means the stock is now outperforming 96% of all other stocks in terms of key performance metrics and technical strength.
Acadia Healthcare stock is considered extended and now out of buy range after clearing the 76.79 buy point in a consolidation.
Looking For The Best Stocks To Buy And Watch? Start Here
One weak spot is the company's 78 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q2, the psychiatric services provider reported 18% earnings growth. Top line growth was flat, matching the prior report's 12%.
Acadia Healthcare stock earns the No. 3 rank among its peers in the Medical-Outpatient/Home Care industry group. AdaptHealth Corp Cl A is the No. 1-ranked stock within the group.
